The North West of England Endocrinology, Diabetes and Obesity Newsletter

Weighing Risks and Benefits of Liraglutide — The FDA’s Review of a New Antidiabetic Therapy

Posted by Angela Paisley on 18 February, 2010


FDA’s summary with regards to approval of liraglutide. Discussion of the potential benefits of improved glycaemic control whilst highlighting potentially serious safety concerns.


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s